As a result, it is reasonable to consider GBM patient tumors treated with CAR T may respond to CAR T therapy by adaptively producing an even more immune-suppressive TME, specifically via upregulating the PD1-PDL1 axis and driving T cell exhaustion in response to IFNγ produced by the CAR T cells. The gene discussed is PDCD1; the disease is glioblastoma.